Drug Combination Details
| General Information of the Combination (ID: C24892) | |||||
|---|---|---|---|---|---|
| Name | Dicoumarol NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Urothelial cancer
[ICD-11: 2C9Z]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Phosphorylation | p38 beta | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | TP53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | RT-112 | CVCL_1670 | Bladder carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Concomitant use of dicoumarol could enhance the cytotoxicity of doxorubicin in urothelial cancer cells with wt-p53 through the p53/p21/p38 MAPK pathways. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Dicoumarol enhances doxorubicin-induced cytotoxicity in p53 wild-type urothelial cancer cells through p38 activation. BJU Int. 2010 Feb;105(4):558-64. | |||
